Clinical trials: Blood Pressure, High
Glaucoma
Short Term Comparative Study of Xalatan With Benzalkonium Chloride vs. Travatan Z Without Benzalkonium Chloride in Healthy Volunteers
Compare the effect of Xalatan with benzalkonium chloride on the ocular surface to those effects observed with Travatan Z without benzalkonium chloride after a single dose
- Trial name
- NCT00468988
- Testing
- Travatan® Z, Xalatan®
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Alcon Research
Essential Hypertension
Efficacy of Amlodipine-Folic Acid Tablets on Reduction of Blood Pressure and Plasma Homocysteine
To evaluate the efficacy of Amlodipine-Folic Acid Tablets on reduction of blood pressure and plasma total homocysteine.
- Trial name
- NCT01956786
- Testing
- Amlodipine-FA tablet,low dose group, Amlodipine-FA tablet,high dose group, Amlodipine
- Where
- 3 sites in China
- Volunteers
- 540 people
- Sponsor
- Shenzhen Ausa Pharmed Co.,Ltd
Hypertension,Essential
Safety and Efficacy of SPH3127 on Treating Mild-moderate Essential Hypertension Patients
SPH3127 tablet is a of renin inhibitor. It is expected to be a new drug for essential hypertension. This is a phase IIa trial which designed to evaluate its efficacy and safety on treating mild-moderate essential hypertension…
- Trial name
- NCT03756103
- Testing
- SPH3127 tablet Dose 1, SPH3127 tablet Dose 2, SPH3127 tablet Dose 3
- Where
- 10 sites in China
- Volunteers
- 120 people
- Sponsor
- Shanghai Pharmaceuticals Holding Co., Ltd
Glaucoma, Ocular Hypertension
A Safety and Efficacy Study of ALPHAGAN® P and LUMIGAN® in Subjects Previously Treated With Latanoprost for Glaucoma and Ocular Hypertension
This study will evaluate the efficacy and safety of either bimatoprost 0.01% ophthalmic solution (Lumigan®) alone or bimatoprost 0.01% ophthalmic solution (Lumigan®) and brimonidine tartrate 0.1% ophthalmic solution (Alphagan® P)…
- Trial name
- NCT01525173
- Testing
- 0.1% brimonidine tartrate ophthalmic solution, 0.01% bimatoprost ophthalmic solution, 0.2% hypromellose lubricant eye drops
- Where
- United States
- Volunteers
- 137 people
- Sponsor
- Allergan
Pulmonary Arterial Hypertension
Study to Assess the Tolerability and the Safety of the Transition From Inhaled Treprostinil to Oral Selexipag in Patients With Pulmonary Arterial Hypertension
This study enrolls patients with pulmonary arterial hypertension (PAH) treated with inhaled treprostinil. During the study, the treatment with inhaled treprostinil will be tapered off and simultaneously replaced with an oral…
- Trial name
- TRANSIT-1 (NCT02471183)
- Testing
- Selexipag
- Where
- 15 sites in United States
- Volunteers
- 34 people
- Sponsor
- Actelion
Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction
Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction
This was a multicenter, randomized (1:1; oral treprostinil to placebo), double-blind, placebo-controlled study in subjects with World Health Organization (WHO) Group 2 pulmonary hypertension (PH) associated with heart failure…
- Trial name
- NCT03037580
- Testing
- Oral treprostinil
- Where
- 82 sites in United States
- Volunteers
- 84 people
- Sponsor
- United Therapeutics
Hypertension
A Real-world Study of the Safety of Hypertension Medication Therapy in Japanese Patients With Naïve Hypertension
This was a non-interventional, secondary use of data, retrospective, cohort study. The data extracted in this study was used as secondary use of collected patient information in the database, Japan Medical Data Survey (JAMDAS)…
- Trial name
- NCT06683768
- Where
- United States
- Volunteers
- 40,563 people
- Sponsor
- Novartis Pharmaceuticals
Ocular Hypertension, Open-angle Glaucoma
Tafluprost-Timolol Fixed Dose Combination Non-Inferiority Study Against Concomitant Administrations
The purpose of this study is to compare the efficacy and safety of the preservative-free fixed-dose combination of tafluprost and timolol (FDC) to concomitant administration of tafluprost and timolol.
- Trial name
- NCT01306461
- Testing
- Timolol and Tafluprost, Fixed Dose Combination of tafluprost and timolol
- Where
- Hungary
- Volunteers
- 401 people
- Sponsor
- Santen Oy
Primary Open Angle Glaucoma
CRISPR/Cas9 Instantaneous Gene Editing Therapy to Intraocular Hypertensive POAG With MYOC Mutation
This study is intented to evaluate the safety, tolerability and preliminary efficacy of CRISPR/Cas9 Instantaneous Gene Editing Therapy (BD113 virus-like particle, also BD113vLVP) in patients with primary open-angle glaucoma…
- Trial name
- NCT06465537
- Testing
- BD113vVLP
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Shanghai BDgene Co., Ltd.
Primary Angle Closure Glaucoma, Primary Angle Closure
Hydrus Microstent and Lens Extraction for the Treatment of Primary Angle-Closure Glaucoma
This study is a prospective evaluation of the Hydrus Microstent for the treatment of Primary Angle Closure (PAC) and Primary Angle Closure Glaucoma (PACG) with adjunctive cataract.
- Trial name
- NCT04622605
- Testing
- Trabecular bypass and Schlemm's canal stent
- Where
- Philippines
- Volunteers
- 31 people
- Sponsor
- Asian Eye Institute
Hypertension, Pulmonary
Safety of Terbogrel in Patients With Primary Pulmonary Hypertension
Study to assess the safety of terbogrel during open-label, long-term treatment in medically stable or improving patients with primary pulmonary hypertension who have completed the 12-week, double-blind randomized trial of…
- Trial name
- NCT02223494
- Testing
- Terbogrel
- Volunteers
- 33 people
- Sponsor
- Boehringer Ingelheim
Hypertension, Diabetes
A Clinical Study to Evaluate Safety & Efficacy of the Combination of Aliskiren, Valsartan & Hydrochlorothiazide in Diabetic Hypertensive Nonresponder Patients
To evaluate the blood pressure lowering effect and safety of aliskiren used in combination with valsartan/hydrochlorothiazide in diabetic patients with essential hypertension, not adequately responsive to the combination of…
- Trial name
- NCT00219102
- Testing
- aliskiren
- Where
- 7 sites in United States, Belgium and 5 more
- Volunteers
- 336 people
- Sponsor
- Novartis
Primary Open Angle Glaucoma, Ocular Hypertension
Non-inferiority of PRO-067 Ophthalmic Solution vs GAAP Ofteno® in Glaucoma or Ocular Hypertension
Aim: To demonstrate the non-inferiority of the PRO-067 ophthalmic solution manufactured by Laboratorios Sophia S.A. de C.V. versus GAAP Ofteno® ophthalmic solution like hypotensive therapy in subjects with primary open angle…
- Trial name
- COMPLIANCE (NCT02801617)
- Testing
- PRO-067, GAAP Ofteno®
- Where
- Mexico
- Volunteers
- 116 people
- Sponsor
- Laboratorios Sophia S.A de C.V.
Hypertension
Glycemic Control Of Carvedilol Versus Metoprolol In Patients With Type II Diabetes Mellitus And Hypertension
To evaluate the effects of two different antihypertensive medications in the drug class of beta-blockers on control of glucose in Type II diabetic patients with high blood pressure.
- Trial name
- NCT00060918
- Testing
- carvedilol, metoprolol
- Where
- 50 sites in United States
- Volunteers
- 1,210 people
- Sponsor
- GlaxoSmithKline
Hypertension, Stroke
A Blood Pressure Regulation and Stroke Risk Evaluation Study in Hypertensive Patients Treated With Eprosartan
The primary objective of the study is to evaluate the proportion of hypertensive patients who achieve regulation of their blood pressure (BP) levels according to the European Society of Cardiology / European School of Haematology…
- Trial name
- NCT01562613
- Where
- 84 sites in Greece
- Volunteers
- 533 people
- Sponsor
- Abbott
Angina, Hypertension
To Demonstrate the Relative Bioavailability of Atenolol Tablets, 100 mg
To demonstrate the relative bioavailability of atenolol tablets, 100 mg.
- Trial name
- NCT00946725
- Testing
- Atenolol (Tenormin) 100 mg Tablets Zeneca (Astra Zeneca Pharmaceutical), Atenolol 100 mg Tablets (Geneva Pharmaceutical, Inc.)
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Sandoz
Essential Hypertension, Primary Hypertension
Assessment of Efficacy and Safety of Amicomed®, for the Management of Essential Hypertension
This is a multicenter, randomized, single-blind, parallel-group study to evaluate the efficacy and safety of Amicomed® compared with Usual Care (UC) over a 24-week treatment period in subjects with essential hypertension (mean…
- Trial name
- NCT06091176
- Testing
- Amicomed®, Usual Care
- Volunteers
- 316 people
- Sponsor
- Newel Health SRL
Arterial Hypertension, CHD - Coronary Heart Disease
Assessment of the Efficacy and Tolerability of the Fixed-dose Combination of Bisoprolol/Perindopril
Study objective - to assess the efficacy, tolerability and adherence of bisoprolol/perindopril FDC in patients with HT and stable CAD in everyday practice.
- Trial name
- STYLE (NCT03730116)
- Testing
- bisoprolol/perindopril FDC
- Where
- Russia
- Volunteers
- 1,909 people
- Sponsor
- Servier Russia
Cirrhosis, Portal Hypertension
Emricasan, an Oral Caspase Inhibitor, in Subjects With NASH Cirrhosis and Severe Portal Hypertension
This is a multicenter, randomized, double-blind, placebo-controlled trial involving subjects with NASH cirrhosis and severe portal hypertension (defined as HVPG ≥12 mmHg as determined by the central reader assigned to this…
- Conditions
- Cirrhosis, Portal Hypertension, Non-alcoholic Steatohepatitis
- Trial name
- ENCORE-PH (NCT02960204)
- Testing
- Emricasan
- Where
- 37 sites in United States, Germany and 1 more
- Volunteers
- 263 people
- Sponsor
- Histogen
Hypertension
Single Ascending Dose Study of Safety and Tolerability of SPH3127 Tablet in Chinese Healthy Volunteers
1. To evaluate safety, tolerability and pharmacokinetics (PK) and pharmacodynamics (PD) characteristics of SPH3127 dose escalation, a single oral dose in Chines healthy volunteers. 2.
- Trial name
- NCT03128138
- Testing
- SPH3127
- Where
- China
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Shanghai Pharmaceuticals Holding Co., Ltd